Carboplatin + paclitaxel
Checked 2026-09-09
Ovarian cancer adjuvant or neoadjuvant (6 cycles); advanced endometrial cancer with pembrolizumab or dostarlimab; NSCLC
One cycle
every 21 days × 6 · about 18 weeks in totalComponents
| Drug | Dose | Route | Days | Note |
|---|---|---|---|---|
Carboplatin Cytotoxic chemotherapy (platinum) | AUC 5-6 | IV | D1 | |
Paclitaxel Cytotoxic chemotherapy (taxane) | 175 mg/m² | IV | D1 |
Cycles
6
21-day cycle
Emetogenicity
High (>90%)
G-CSF
Not routine
Notes
- Carboplatin AUC 4 or above is classed as highly emetogenic by NCCN; three-drug prophylaxis including an NK1 antagonist.
- RUBY: dostarlimab 500 mg every 3 weeks × 6 then 1,000 mg every 6 weeks up to 3 years. NRG-GY018: pembrolizumab 200 mg every 3 weeks × 6 then 400 mg every 6 weeks.
Used in
Source
GOG-158 (Ozols), JCO 2003; NCCN Ovarian Cancer
Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.
Other regimens for these cancers
Trastuzumab deruxtecan 5.4 mg/kg
HER2-positive metastatic breast cancer second line; HER2-low or ultralow after chemotherapy or endocrine therapy; HER2-mutant NSCLC
every 21 days
Pembrolizumab + pemetrexed + platinum
Metastatic non-squamous NSCLC without EGFR/ALK alteration, first line, any PD-L1
every 21 days × 4
Pembrolizumab + carboplatin + paclitaxel
Metastatic squamous NSCLC, first line
every 21 days × 4
Nivolumab + ipilimumab + 2 cycles of platinum doublet
Metastatic NSCLC without EGFR/ALK alteration, first line
every 21 days
Osimertinib
EGFR ex19del or L858R NSCLC: first line metastatic (FLAURA), adjuvant for 3 years after resection (ADAURA), after chemoradiation (LAURA)
every 28 days
Cisplatin + vinorelbine (adjuvant)
Completely resected stage IB (4 cm or larger) to IIIA NSCLC
every 28 days × 4
Chemoradiation then durvalumab (PACIFIC)
Unresectable stage III NSCLC without progression after platinum-based chemoradiation
every 28 days × 12
Cisplatin + etoposide (EP)
Limited-stage SCLC with concurrent thoracic radiotherapy; stage III NSCLC chemoradiation; high-grade neuroendocrine carcinoma
every 21 days × 4